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ABSTRACT
This paper engages critically with the global assemblage framing
sickle cell and thalassaemia disorders as a ‘global health crisis’; and
the promise of genomics, largely DNA-based carrier/pre-conceptual
screening, prenatal diagnosis with a view to terminations, deployed
in framing a solution to these historically racialised spectrum of
diseases as essentially preventable. Sickle cell and thalassaemia are
recessively inherited, potentially life-threatening haemoglobin
disorders with signiﬁcant variation of severity, often needing life-
long treatment. I argue that the re-classiﬁcation of inherited blood
disorders (IBDs) under ‘prevention and management of birth
defects’ by the WHO in 2010 can be read as an ethical moment
within the ‘globalising turn’ of IBDs and the use of genomics in
addressing structural inequalities underpinning health in low- and
middle-income countries. Using an Indian case study, the paper
aims at ﬁrst examining the language of risk through which genes
and IBDs are mapped onto pre-existing populations (e.g. caste and
tribe) as discrete, categories. Second, it discusses the likely social
and ethical ramiﬁcations of classifying these recessive gene
disorders as essentially preventable, despite cheaply available
diagnostic tests and treatment options available in most countries
in the South.
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Introduction
Anticipating the philosophical reverberations of the notion of genetic error (mutation)
introduced at the turn of the twentieth century, Canguilhem (1991, 172) poignantly
observed, ‘To be sick is to have been made false, to be false, not in the sense of a false
bank note or a false friend, but in the sense of a “false fold” or a false rhyme’. We have
since identiﬁed 437 mutant genes related to 286 severe childhood recessive disorders,
using relatively cheaper and efﬁcient new generation sequencing. The idea of genetic error
as a ‘false fold’ or a ‘false rhyme’ now implies that it can and must be ‘undone’. Preimplan-
tation diagnostics and genome editing techniques pose unique questions for how we
address embodiment, genetic risk, inheritance, impairment and disability (see Masae, this
collection). Equally, stem cell transplants and gene therapies open up new frontiers of a
‘moral economy of hope’ (Rose and Novas 2005). The challenge facing anthropologists
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that I ﬁnd particularly exciting, as outlined by Margaret Lock is: how to recognise the
materiality and centrality of biological difference to human health and wellbeing, while
critically engaging with the imminent dangers of molecuralisation of race and its implica-
tions for essentialising, dehistoricising and depoliticising the biology of human difference
and structural inequalities underpinning health (Lock 2012, 131; also see Gibbon 2016;
Pagano 2014; Calvo-Gonzalez 2013; Fullwiley 2007; Palsson 2007, 152–162).1
This paper engages with the global assemblage framing sickle cell and thalassaemia – a
closely related spectrum of two historically racialised, recessively inherited blood disorders
(IBDs) – within a ‘crisis rhetoric’ of contagion in public health being extended to non-
communicable diseases across low- and middle-income countries (LMICs; see Parkin,
Krause and Alex 2013; Reubi, Herrick and Brown 2016). More speciﬁcally, it focuses on
the use of genomics, largely DNA-based carrier / antenatal/pre-conceptual screening and
prenatal diagnostic tests (with a view to terminations), deployed in governing these disor-
ders as essentially preventable in LMICs (WHO 2002; 1994). I argue that the re-classiﬁca-
tion of IBDs under prevention and management of birth defects by the WHO (2010) can
be read as an ethical moment within the ‘globalising turn’, aimed at addressing structural
inequalities underpinning health in LMICs. It unravels ‘competing truth claims’ seeking
to address the burden of disease, death and the suffering of children within the context of
international and national developmental goals (Shiffman 2009). An Indian case study is
used to analyse how the language of risk, prevention and elimination of IBDs, silences the
racialisation of historically marginalised ethnic/social groups embodying these ‘deleterious
genes’ and the threat they seem to pose to public health within a speciﬁc national context
(see Calvo-Gonzalez 2015; Thomas and Clarke 2013; Cavalcanti and Maio 2011; Tapper
1999).
In this paper, signiﬁcant differences in the broader histories of sickle cell and thalassae-
mia, brieﬂy touched upon later, are ignored so as to focus on the space carved by interna-
tional and national policies where these disorders are placed together.2 My analysis draws
on three main data sources collected over the past four years in anticipation of a grant for
a detailed ethnography3: (i) policy documents related to IBDs within central, state and
international domains, (ii) scientiﬁc papers and community surveys (often citing data
from the Indian Council of Medical Research (ICMR) or the Anthropological Survey of
India) and (iii) media reportage of recent events and policy issues raised by prominent
health activists and non-governmental organisations (NGOs). In particular, I have shad-
owed Sickle Cell Society India (SCSI) – interviewing key members, observing four com-
munity engagement events in Maharashtra (December 2016), and observing their
participation at the 3rd Global sickle cell congress in Bhubaneswar (February 2017). My
objective is not to validate a particular truth claim rather to identify some of the ‘therapeu-
tic gaps’ (as in Simpson 2007) being addressed through diverse forms of activism, and
state and non-state partnerships in view of particular, local health interventions (Biehl
2016; Simpson 2007).
The two aims of the paper are to discuss the likely social and ethical ramiﬁcations of
classifying a complex, heterogeneous spectrum of recessive gene disorders as essentially
preventable, and focusing on the potential suffering of infants and children (excluding
adults), despite cheaply available diagnostic tests and treatment options available in most
countries in the South. Second, I want to analyse the seemingly contradictory inﬂuences
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of the policies and practices of different actors on the governance of health and reproduc-
tive rights of marginalised populations in poorly regulated healthcare systems in countries
such as India (Gammeltoft and Wahlberg 2014; Unnithan-Kumar 2009; Chattoo 1991). In
problematising the notion of prevention of ‘birth defects’, one is not contesting the impor-
tance of the materiality of IBDs or the suffering of children, especially within the context
of extreme poverty (see Das 2015; Das and Das 2006). Instead, as Didier Fassin reiterates:
… saving babies, … and bringing assistance … is a collective responsibility … . But the fact
that this is beyond dispute does not imply that we should not challenge the way the mission
is conducted, the implicit logic it reveals, the speciﬁc interests it may serve, and the contradic-
tions and misconceptions that it may provoke. (Fassin 2013, 128)
One of the major contradictions explored by Fassin through his work on AIDS in South
Africa, and Veena Das in her study of health of the urban-poor in India, relates to the
abstract notion that all lives are equal and must be saved, and how international humani-
tarian policies on aid and state interventions and distribution of resources, in practice,
reﬂect different values placed on life and ‘letting die’ (Das 2015, 181–202; Fassin 2013,
2007 following Foucault 1991, 2003).
Before outlining the Indian policy context, a note on the reclassiﬁcation of IBDs is
helpful to set the global scene.
Crisis rhetoric, politics of classiﬁcation, and (in)visibility of suffering
In her evocative ethnography of ‘sickling’ in Senegal, Fullwiley outlines the struggles of
clinicians, patient advocates and NGOs, since early 1990s, in challenging the political
neglect and invisibility of sickle cell by the World Health Organization and the United
Nations (Fullwiley 2011, 9–10). IBDs have since been reconstituted as a ‘global health cri-
sis’ posing speciﬁc challenges and solutions for high-prevalence countries in the South
(Piel et al. 2014; Weatherall and Clegg 2001; WHO 1994). David Weatherall, a renowned
haematologist trying to raise the proﬁle of IBDs (paradoxically), observed:
… It has been estimated recently that if the survival rate of children with sickle cell anemia in
Africa increases to only one half the African norm, more than 6 million Africans will be liv-
ing with sickle cell anemia … . We are, in effect, sitting on a genetically determined time
bomb. It is time for action. (Weatherall 2010)
Importantly, this impending crisis is perceived to have signiﬁcant implications well
beyond the borders of high-prevalence countries in the South, as can be gleaned from the
following excerpt from a widely cited Lancet paper, forecasting the redistribution of sickle
gene as a global phenomenon (co-authored by Weatherall):
… . International migrations can also have a long term effect on public health through the
introduction of deleterious genes into populations in which they were previously absent …
(Piel et al. 2014, 1)
(Further on)
In the absence of a curative treatment for sickle cell disorders,… prevention programmes are
essential strategies to reduce the subsequent long term economic and health burden. Rather
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than suggesting strict immigration policies, our ﬁndings emphasise the need for an interna-
tional approach to prevent such genetic health disorders globally. (Piel et al. 2014, 6 my
emphasis)
Needless to say, the ‘global assemblage’ IBDs as a ‘crisis’ can be read in several registers of
competing ‘truth claims’ (Shiffman 2009, 608), situated across a contingent, heteroge-
neous, unstable, partial, and contested ﬁeld (Ong and Collier 2005, 11–12). Despite differ-
ent bio-political underpinnings of interventions for the prevention and management of
IBDs, three sets of issues framed within the neoliberal project of global governance of
health and ‘humanitarian morality’ emerge (Thomas and Clarke 2013): (i) a concern for
the welfare of affected children in LMICs; targets for reducing IBD-related infant and
under-ﬁve morality, (ii) the economic logic of reducing the long-term costs of care, antici-
pating greater demand for treatment as more children are diagnosed and survive to live
with such genetic disorders, and (iii) a public health approach to prevention focusing on
potential carriers, who themselves are ‘healthy’ but can ‘pass on’ the disease to their chil-
dren through reproduction. Hence, carriers reify body as a ‘frontier of risk’ (Lock 2012)
and have been the focus of state control and prevention policies (Tapper 1999; Cavalcanti
and Maio 2011). Such articulations reﬂect a conﬁguration of inﬂuential actors and strate-
gic epidemiology that shapes the ‘biolegitimacy’ of particular rights related to health
rather than empirical evidence reﬂecting the needs of those affected per se (Fassin 2012,
51). For example, while sickle haemoglobin affects10 per cent of the population in Sene-
gal, 30 per cent of state health budget is committed to HIV/AIDS programmes (Fullwiley
2011).
Previously, the International Classiﬁcation of Diseases (ICD) 10 included thalassaemia
(D56) and sickle cell disorders (D57) in Chapter III, covering ‘diseases of the blood and
blood forming organ’, rather than Chapter XVII on birth defects and chromosomal
abnormalities. Subsequently, the 63RD World Health Assembly report on birth defects
included IBDs in the list of the ‘most common serious congenital disorders’. Here, both
genetic and environmental congenital disorders ae lumped together, making a broad case
for prevention – an ethically contentious issue that cannot be explored here. More speciﬁ-
cally, the document links prevention of IBD-related births to the Millennium Develop-
ment Goal (MDG4) of two-thirds reduction in under-ﬁve mortality by 2015. It
emphasises several interventions for preventing births, before outlining standard treat-
ments and beneﬁts of newborn screening- an important preventive strategy aimed at early
diagnosis, known to produce better treatment outcomes with reduced mortality for chil-
dren (WHO 2010).
Humanitarian concerns about potential suffering of children in LMICs, where 70–90
per cent of affected babies are expected to die before the age of ﬁve, are based on an
assumptions that no treatment is available or economically feasible (for a critique, see Fot-
trell and Osrin, 2013 [on Piel et al. 2014]; Fullwiley 2011). On the contrary, newborn
screening for sickle cell in Ghana, with the use of antibiotics for preventing known infec-
tions, and adequate treatment and compliance for beta thalassaemia in India, show that
average life expectancy around 55 years can be achieved, comparable with outcomes in
the North (Grosse et al 2011; Agarwal 2004). The likely reverberations of a focus on pre-
vention (of births) for particular populations will now be explored through the speciﬁc-
ities of an Indian case study.
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Mapping genes onto cast, tribe and race: the ‘shifting metonymies’ of haemoglobin
variants
India provides an important conceptual link to the broader history of globalisation of
IBDs, and the discursive practices through which complex genetic mutations are mapped
on to pre-existing ‘populations’. The point at issue here is not that some of the gene var-
iants resulting in IBDs might be more common among certain ethnic groups or regions
of the world/India.4 Rather, in mapping genetic differences on to existing social divisions,
genomics both sustains and challenges ideas of descent, ancestry, origin, ethnicity and
nation (Calvo –Gonzalez 2015; Beaudevin 2013; Carter and Dyson 2011). As cogently
argued by Kent, Santos and Wade (2014, 737):
These genomic techniques involve the concept of biogeographical population: a set of people
thought to have evolved a genetic proﬁle in a given location and transmitted to their descend-
ants. A key question is how to deﬁne such populations - given that humans share 99 percent
of their DNA – and whether these populations relate to modes of social classiﬁcation, such
as ethnic group, race, nation, region, community, and so forth.
In their classic article, Lehman and Cutbush, ﬁrst documenting the presence of sickle cell
gene in India, summarised the thesis of its ‘African’ origin as follows:
The aboriginal tribes were chosen as the group in whom a search for African blood features
appeared most likely to have positive results (Nilgiri Hills, South India).… . These ﬁndings
lend support to the idea of an Indian migration to Africa in prehistoric times… (Lehmann
and Cutbush 1952, 404)
The story of the ‘Indian-Arab haplotype’ is central to destabilising the notion of sickle cell
as the archetype of a racialised, black disease – if only to be replaced by a mesh of local idi-
oms of caste, tribe, race, ethnicity and class. Equally, the Indian case study also challenges
the notion of genes and genetic disorders as stable, mutually exclusive biological catego-
ries (also see Beaudevin 2013). Thus, while 6–7 common mutations account for 80–90
per cent of the mutant alleles associated with signiﬁcant forms of sickle and thalassaemia,
clinical literature highlights the molecular heterogeneity of around 64 mutations, with
complex homozygous, heterozygous and double heterozygote forms – some less benign
than others (Verma, Saxena and Kohli 2011).
It is fascinating to note how the debates surrounding haemoglobin variants (caus-
ing IBDs) in India mirror, what Mukharji (2014, 145) evocatively describes as, the
myth of origin and, ‘the shifting metonymies of Blood group B’—perceived as a
genetic marker of racial groups and caste hierarchy at the turn of the twentieth cen-
tury (see Sen 1960). Ever since the ﬁrst Anthropological Survey of India (1950s),
data on incidence of IBDs by jatis (sub-caste) and tribe is cited in studies by clini-
cians as well as physical anthropologists. The legacy of sickle cell being essentially a
‘tribal disease’ persists, despite evidence of signiﬁcant variations within tribal groups,
following similar kinship and (consanguineous) marriage patterns (Urade 2012;
Mohanty and Das 2011). This is not the place to engage in a semantic discussion on
the pre, colonial and post-colonial intersections of caste, tribe, race, religion and eth-
nicity in relation to the strongly contested nationalist theories of Dravidian – Indo-
Aryan races. Sufﬁce it to mention here that the adivasi (so called aboriginal) or tribal
groups sit awkwardly squeezed between the dominant notions of caste/Hindu society
34 S. CHATTOO
on one hand and nationalist/civilizational and developmental discourses on the other
(for a broad overview see Xaxa 2003; Bates 1995).
The colonial history and administrative function of categories such as ‘scheduled caste’,
‘scheduled tribe’ and ‘other backward classes’ invoke notions of race, ethnicity as well as
socio-economic ‘backwardness’ (see Nigam 1990 on the Criminal Tribes’ Act 1871). Sub-
sequent to several tribal movements over land rights, loss of livelihood, and authoritarian
public health interventions, since independence, these categories have served as a basis of
anti-discrimination laws and reservation policy in education and employment, guaranteed
under Article 341 (1) of the Indian Constitution (see Berreman, 2009). Hence, ‘strategic
essentialism’, in Glick Schiller’s phrase (2005), is important for seeking recognition and
redressal of socio-economic inequalities at a policy level – albeit one that both subjectiﬁes
and objectiﬁes the minority ethnic/religious group in question (see Xaxa, 2003).
Irrespective of these features, the intriguing question for this discussion remains: what
purpose do these categories serve in clinical literature? The following excerpt from a paper
on the challenges of genetic counselling in tribals, using 2001 Census ﬁgures, is
illustrative:
There are many (pre/agricultural/nomadic) tribal groups identiﬁed for their speciﬁc biologi-
cal constitution, anthropogenetic characterization, distinct cultural and linguistic patterns
and conﬁnes geographical localization… In many tribal groups distinct Negroid feature of
appearance is seen (e.g. Jarawas, Ongs of Andamans…) whereas in many, mongoloid origin
is traced (Khasi, Garos of North East)… .… Studies done on blood groups and immunity
related genes have shown … sets of alleles which are exclusive to certain geography and eth-
nic groups. (Mohanty and Das 2011, 562–63)
However, like others, the authors go on to concede that
Earlier postulations … of HbS gene being only limited to tribal and lower caste population
have been changed as the gene has been found in almost all the communities… with prepon-
derance among the Indian tribes. In Orissa, the gene is prevalent among the general castes
(0.3–20.7%), scheduled castes (0–8.9%) and scheduled tribes (0–5.5%). (ibid, 563)
Even when social and geographical mobility of tribal groups is recognised within clinical
and policy documents, the threat of the mutant gene spreading to urban geographies and
miscegenation looms large (Ghosh, Colah and Mukherjee 2015, 506). While 635 tribal
groups, living predominantly in inaccessible rural and forest areas, constitute 8.8 per cent
of the Indian population, they represent over 25 per cent of the poorest across India. Their
lives are still characterised by disproportionately high levels of malnutrition, anaemia,
common infections as well as higher infant mortality rates of 100 per thousand rather
than overall 80 for India, marking the ‘local biology’ of the disease (Jan Swasth Sahyog
2016). It is not surprising that the Editor of a special issue on tribal health, in the Indian
Journal of Medical Research, qualiﬁed IBDs as ‘poor man’s diseases’ (Singh 2015; also see
Colah et al. 2015, 510). The importance of these structural features of poor health indices
of tribal children for prioritising prevention of IBDs over better and accessible care will be
discussed later.
Locating IBDs within health policy in India: the ‘seeping in’ of the local and the global
To provide a broad policy overview, India is estimated to have the largest number of car-
riers of IBD in the world, around 42–45 million of a population of 2.1 billion.
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Approximately 7500–12,000 babies with Beta thalassaemia and 15,000–25,000 babies with
sickle cell disorders are born each year (Colah et al. 2015).5 The epidemiological picture is
characterised by striking inequalities in access to appropriate, long-term healthcare across
public and private sectors, especially for the poor, rural and tribal communities living at
the margins of the state- as suggested earlier (Government of India 2016b; Chatterji and
Gunjan 2007). Even though cheap diagnostic kits and generic drugs as well as curative
bone-marrow and cord- blood stem cell transplants are widely available at several state
and private healthcare centres across India, only 5–10 per cent of children with thalassae-
mia receive optimal care (Malik et al. 2010; Chandy 2008).
Lack of access to cash and affordable healthcare pushes roughly 39 million Indians
below the poverty line (Reddy et al. 2011). As elsewhere in the world, access to treat-
ment has been a central feature of health activism since mid-1999s, with public-pri-
vate partnerships mediating the role of giant pharmaceutical companies (Nguyen
2005). However, following Biehl, we must ask, are there ways in which these afﬁlia-
tions, ‘… endow states with new (sometimes abusive) powers while also diversifying
claims to citizenship’? (2016, 130). I want to foreground this question by analysing
how the two main constituencies – (state) public health policy, and NGOs and
online patient communities – represent the needs of people with IBDs and engage
with policies of prevention outlined earlier.
It is important to note that right to healthcare is a positive rather than a protec-
tive right within the Indian Constitution. However, since the 1990s, in response to
several public interest litigation cases, the Supreme Court has treated right to health
as an extension of the fundamental right to life and dignity guaranteed under article
21 of the constitution (see for example, Archive Indian Express, 19/12/2013, for one
such petition ﬁled by parents of an 8-year old: http://archive.indianexpress.com/
news/hc-seeks-reply-from-govts-aiims-on-free-treatment-for-thalassemia-patients/).
Individual states are responsible for maintaining data, providing healthcare and regu-
lating professional practice, though both state assembly and parliament can legislate
on health policy. There are no national policies related to IBDs in India, though
periodically these might be nested within larger health programmes. For example,
the National Rural Health Mission (NRHM) (set up in 2005 to help the states
achieve the Alma-Ata target of universal health coverage) focuses on vulnerable
groups, and reducing under- ﬁve and maternal mortality rates, in line with the
(expired) MDGs 4 and 5. Closely related Rashtriya Bal Swastha Karyakam (RBSK,
national child health and early screening and intervention programme for 0–18 years,
2013) covers 30 conditions, and item 30 includes congenital disorders and IBDs.
States and Union Territories, however, have the option of including screening and
intervention policies, based on local epidemiology.
Similarly, the Working Group on the Disease Burden for the 12th Five-Year Plan
(Section 2, item 21), covers prevention and management of IBDs within programmes
of prevention and rehabilitation of disability, highlighting cooperation between state
and NGOs, perceived as representing the interests of patients (Government of India
2012). These NGOs, however, are often set up by local clinicians/activists working
closely with the state and/or the ICMR. Following a consultation, the National
Health Mission recently published guidelines on prevention and control of IBDs
which, however, are more on literature from Cyprus and elsewhere than the needs of
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local patient populations across India (Government of India, 2016a). In letter, the
guidelines refer to the WHO recommendations on ethics of non-directive counsel-
ling, informed consent and cultural sensitivity about plural reproductive norms and
disability (National Health Mission, 2016). The reality of how screening and counsel-
ling are actually implemented at state and local levels, especially in rural and tribal
areas with high levels of minimal literacy, has received little attention (Mohanty and
Das 2011; Patra and Sleeboom-Faulkner 2010, 73–75).6
Gujarat Sickle Cell Anemia Control Society is a good example of the ‘bioavailabil-
ity’ of vulnerable groups (cf. Cohen 2004) within the space carved by the NRHM, as
well as the state-NGO partnerships outlined in the 12th Plan above. The Society was
set up in 2011 by a group of clinicians in the state service to ‘better integrate’ the
Sickle Cell Anemia Control Programme (Gujarat Health Government portal n.d).
Supported by the NRHM and the local health authorities, the plan was piloted in 5
districts in South Gujarat in 2006, later extended to 12 tribal districts involving 446
centres by 2013–2014. The team worked in collaboration with the Indian Red Cross
Society, and Valsad Raktdan Kendra, a local (NGO) blood centre catering to the
needs of sickle cell affected families since 1984. The three main goals of the Pro-
gramme were (i) to eliminate all births related to SCD by 2020 (MDG4 target), (ii)
prevent deaths from SCD, and (iii) to improve the health and quality of life of peo-
ple suffering from these disorders (Gujarat Health Portal, nd). Implemented by the
epidemic branch of the Ministry of Health, it was called sickle cell swa (self) surakh-
sha (protection) abhiyan (movement) (Patel et al. 2013). The target of reducing
under-ﬁve mortality (MDG4) was translated into a rhetoric of no births of children
with SCD by 2020; while attempts at reducing maternal mortality (MDG5) resulted
in an increase in institutionalised births, leading to a higher number of prenatal
diagnoses and terminations carried out for sickle cell. Antenatal carrier screening
was ‘offered’ to all women on Mamta divas (mothering day) designated for immuni-
sation in the tribal areas (Department of Health and Family Welfare (nd), 22). On a
positive note, the policy included newborn screening, access to free treatment and
follow up for children and adults diagnosed in tribal areas. The Commissioner for
Health received a national award for successful outreach in the tribal areas, portray-
ing a success story.
However, there has been little discussion on how the antenatal and newborn screen-
ing was implemented alongside community screening of children and adolescents, pro-
moting an ethic of genetic exogamy. Gujarat is not the only state where carriers are
advised to match their genetic kundali (proﬁle/ test result) rather than janam kundali
(horoscopes, widely used by Hindus constituting 80 per cent of the population) in
arranging marriages. The catchy soundbite pre-empts the potential risk. Two carriers
together have a 25 per cent chance in each pregnancy of having a homozygous baby (or
25 per cent risk of having a normal baby and 50 per cent chance of having a heterozy-
gous/carrier). Despite positive, though contradictory, promises of cash rewards for those
willing to marry a person with sickle cell anaemia, community screening can reinforce
stigmatising attitudes, especially towards young girls and women who might face
greater discrimination within their community (Patra and Kumar 2010; Gupta 2010;
Chattopadhyay 2006).
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The current Prime Minister, Narendra Modi (Gujarat Chief Minister, when the above
policy was implemented), has endorsed similar projects at a national level. The most
extensive of these being the Jai Vighyan (celebrating science) thalassaemia control pro-
gramme, based in six high-prevalence cities, supported by the IICMR (Mohanty, Colah
and Gorakshakar 2008). Furthermore, the Ministry of Tribal Affairs planned to screen
5 million tribal children across 10 tribal dominated schedule V states, starting with
schools and hostels run by the Tribal Welfare Department and community groups, advis-
ing them against marrying a carrier (The Economic Times, 4 May 2015). A glimpse of the
relationship between the state health ofﬁcials and these tribal groups, in the following
report, is reminiscent of the Raj:
In tribal society the different socio-cultural activities revolve round gods and spirits… .
(assuming they are endogamous) Those who were detected to have sickle cell gene, were
asked to tattoo their hands in the form of god and they were told that they should not get
married to another individual with similar god. This worked out well amongst young tribal
adolescents of Satpura hills among whom the selection of partners is still done by young girls
and boys themselves. (Mohanty and Das 2011, 567)
The economic logic of such national ‘missions’ is summarised in a Delhi Ministry of
Health Report, stating that the public health costs of treating about 2000 children born
with thalassaemia each year in Delhi (100,000–120,000 rupees a year) are ‘unbearable’. ‘It
would therefore be preferable to prevent the birth of a thalassaemia child. This can be
achieved through screening of pregnant women and school children for thalassaemia car-
rier state’ (Ministry of Health 2014; also see Gupta 2010, 48). The use of mandatory car-
rier screening of pregnant women, with a view to identifying ‘high risk’ couples, who are
advised termination following a positive diagnosis, in conjunction with provision of free
blood and chelation therapy offered in state hospitals in Delhi and Gujarat, is a good
example of ‘benign authoritarianism’ (cf. Das 2015, 200–201). Needless to say, some
health professionals are critical of the ethics of population screening in remote, rural
areas, where no treatment or follow up is provided (personal conversation Yogesh Jain,
Director JSS, London, 28 April 2017).
The tensions inherent in the notion of eliminating genetic disorders, and carrier
screening of children and young adults, however, are equally reﬂected in the practices of
NGOs and online patient support groups. In Maharashtra, Rotary Club of Mumbai (sup-
ported by TIF, staunch supporters of prevention) and We Care Trust run carrier screen-
ing programmes in schools and colleges, persuading head teachers and college principals
to ‘motivate children’ to undergo screening. They also organise community campaigns,
advertising car bumper stickers with the message – ‘check your blood not horoscope – to
nip thalassaemia in the bud’ (We Care Trust, homepage, http://www.wecaretrust.net/).
Clearly, these NGOs ﬁll in important gaps in state provision for information and social
support -though, sadly, with little reﬂexivity about how their own practices might rein-
force the negative imagery of IBDs and associated notions of impairment and disability
within the wider society.
While sickle cell organisations are fewer in number and less visible virtually,
despite ﬁghting for small pots of money locally, they might work together with n a
larger thalassaemia organisation (as in Delhi and Bangalore). These NGOs can pro-
vide practical support, subsidised tests, treatment and welfare advice, as well as act
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as a pressure group for health issues of equity and change (see Unnithan and
Heitmyer 2012). Some of the battles fought by small organisation, such as the SCSI,
are quite exemplary, as explained below.
SCSI and Ramteke’s crusade for justice and equity: taking on the state
I ﬁrst met and interviewed Sampat Ramteke, a retired superintending engineer and Presi-
dent SCSI, in March 2015, at his residence in Nagpur. Ramteke’s journey into the world
of sickle cell, prompted by his son’s illness, is documented in a short tele-ﬁlm entitled
(translated), I kept walking along with life (www. Sampat ramteke/ me Zindagi ka saath
nibhata chala gaya). Born into a poor scheduled caste (Mahar) agricultural family from a
remote village in Chimur, Chandarpur District, Ramteke did exceptionally well to get a
diploma in engineering, progressing to a senior position in a coal company. His biograph-
ical details are central to the aims and functioning of SCSI. Ever since his son’s diagnosis
about two decades ago, he has worked ceaselessly to raise awareness about the condition,
lobbying for better medical and welfare support especially for the rural and socio-eco-
nomically deprived families. His tiny ofﬁce is lined with meticulously ﬁled correspon-
dence with bureaucrats and newspaper cuttings related to his work. Rather than the
logistics of how this tiny organisation of seven executive members operates in relation to
the state, without external funding, I want to focus on some of the policy interventions
they have successfully lobbied for.
Ramteke explained how one needs to ‘get under the skin’ of appropriate legisla-
tion, and the perseverance and political acumen required in ﬁghting the bureaucracy,
to achieve a goal that might take years. One of the eight ‘schemes’, proposed by
SCSI and now implemented by the Maharashtra government, was to provide a free
bus pass to parents/patients living in remote villages, to help them travel to a treat-
ment centre. A trip costing a family roughly 400 rupees can, at times, make the dif-
ference between life and death, in accessing timely care for children prone to ‘crisis
events’ (Times of India, Nagpur, 11 December 2015). Furthermore, following advice
from SCSI and an expert panel, Maharashtra State Secondary and Higher Education
Board, since 2013–14, have kept a provision of 20 minutes extra time for each ques-
tion to be availed by sickle cell patients/students writing their class X and XII Board
examinations (Times of India, Nagpur Today, 10 June 2013). More importantly,
in January 2013, SCSI challenged the exclusion of sickle cell from the (Draft) Rights
of Persons with Disability Bill (RPWD) 2012, at an important hearing of
the National Human Rights Commission on the issues of scheduled castes and
scheduled tribes. At that stage, thalassaemia and haemophilia had been incorporated
within an expanded, original list of disabilities drafted in the RPWDB Bill, 2012. The
relative invisibility of sickle cell, within such policy contexts, largely reﬂects its clini-
cal variability, periods of intermittent painful crises and adverse health events
interspersed with stable periods where patients may not see a doctor for months or
even years. In contrast, the need for regular blood transfusion and chelation treat-
ment brings families and patients with b thalassaemia into greater contact with
health professionals, blood banks and NGOs that are better resourced and urban
centred.
Taking recourse to metrics, Ramteke convincingly argued that sickle cell causes
multiple disabilities, affects nearly 1.4 million children and adults, twice the number
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affected by the other two disorders put together, largely from remote, rural and tribal
areas. (Times of India, Nagpur, 29 January 2013). In a signiﬁcant move, he
approached the Chair of the National Commission on Scheduled Castes and the Par-
liamentary Committee on Scheduled Castes and Scheduled Tribes (Times of India,
Nagpur, 19 April 2013). Subsequently, the revised RPWD Bill of 2014, providing sig-
niﬁcantly enhanced rights and entitlements for people with disabilities, was extended
to19 conditions including sickle cell (Kala and Shankar 2015). On the day the Bill
was passed (16 December 2017), we were in Gadchiroli for the state sickle cell week.
The sense of pride and jubilation was palpable in the team, as friends and colleagues
kept ringing to congratulate Ramteke over his success.
Interestingly, in our conversations and public meetings, Ramteke underplays the
notion of sickle cell being a ‘tribal disease’. In his marg darshan (literally, path show-
ing) speeches at community awareness events that I attended, he would pose a (ret-
rospectively rhetorical) question to his audience, ‘Which jati (caste) do you think is
most affected by sickle cell?’, or ‘Why do you think, people get this disease?’ At
times, the response was anecdotal reference to people who eat ‘gaye ya baiel ka mas’
(beef/ bull, denoting ‘other’, lower castes or tribal people contravening dominant
(idealised) Hindu norms of a diet free of meat and/or beef. He then pulled out an
extensive list of castes/jatis and tribes affected by sickle cell, based on published sci-
entiﬁc reports; reiterating that sickle cell can affect people from different religious,
caste and ethnic backgrounds.
Shiffman uses ‘policy window’ for a moment in time when global (national/local) inter-
ventions are favourable to a cause, and particular sentiments are deployed for a greater
impact (2010, 2045). Ramteke researches his ‘facts’ and uses every ‘policy window’ to gal-
vanise support across several platforms – welfare rights of children, women, the disabled
as well as the marginalised SCs and STs—with his ‘pen power’ and sheer perseverance.
Ironically, one of his ‘missions’ is the implementation of legislation similar to the infa-
mous Sickle Cell Anemia Control Act 1972, introduced by President Nixon. The Act,
deemed central to achieving full citizenship rights for black Americans during the Civil
Rights Movement in the USA, also generated resistance to the widespread discrimination
in education and employment, and carrier screening perceived as a form of ‘racial geno-
cide’ (see Wailoo 2017; Tapper 1999; Duster 2003). However, Ramteke is not alone in his
belief in mandatory carrier and antenatal screening as a progressive step towards achiev-
ing a ‘sickle cell free’ India. I turn brieﬂy to this theme and its contradictions in the penul-
timate section below.
Contradictions within a crisis rhetoric – the promise of genomics and a nation free of
thalassaemia?
On World thalassaemia Day (8 May) this year, Shobha Tuli, President,7 Thalassaemics
India, called for a national policy on thalassaemia to prevent, control and provide treat-
ment across India – the designated ‘thalassaemia capital’ of the world (Afhshan Yasmin,
The Hindu, Health, ‘Time for a national policy on thalassaemia’, 7 May 2017). Namitha
K. Malur, a Bengaluru based health researcher and activist (herself a thalassaemia
patient),8 updated her Facebook proﬁle with the following message: ‘On the eve of the
world thalassaemia day I wish for thalassaemia free India’ – echoing the message posted
on the TIF website.
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In response to an intensive campaign led by Namitha and the Thalassaemia and Sickle
cell Society, Bengaluru, the Karnataka state government announced a series of measures
on the World Thalassaemia Day, including free transfusion and treatment for thalassae-
mia, sickle cell and haemophilia patients irrespective of income, and free antenatal screen-
ing for pregnant women (up to 12 weeks). At a press conference following the
announcement, Namitha outlined the demands of her constituency: (i) a national
policy on IBDs, (ii) full inclusion in Disability Bill to avail 4 per cent reservation in
jobs and education (currently limited by the level of certiﬁed disability), and (iii) full
inclusion in the national rare diseases policy (the New Indian Express, 9 May 2017).
The reference to inclusion of IBDs under rare diseases policy is strategic. The policy,
drafted by Namitha and her colleagues from several institutions, in March 2016,
(Image 1. Source Facebook status, TIF, 8 May 2017).
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highlighted the need for public-private investment in diagnostics, orphan drugs and
curative gene therapies, for an estimated 70 million patients across India (The Times of
India, 2 March 2016).
I ﬁnd the juxtaposition of images of gene therapies and orphan drugs alongside meta-
phoric images of an epidemic of carriers spreading the disease, and the disablist reverbera-
tions of elimination of thalassaemia (or sickle cell), disturbing and hard to grasp.
Similarly, a ﬂurry of online posts in praise of a recent Bill on compulsory premarital
screening, passed in the Pakistan National Assembly, did not touch upon the thorny ethi-
cal issue of mandatory carrier screening and its social ramiﬁcations (see Raz 2010). I am
not denying that Namitha along with other academics, or indeed other patient activists,
might be having these debates elsewhere. Indeed, I am aware of the several forums on dif-
ference and disability supported by Namitha and the Centre for Health Ecologies and
Technology (where she works).
We saw how, despite their contrasting urban/rural bae and styles of activism, both
Ramteke and Namitha adopt forms of ‘strategic essentialism’, increasingly taking recourse
to disability rights legislation in ﬁghting for the rights of people with IBDs. However, in
uncritically advocating or appropriating state policies prioritising prevention aimed at
eliminating the disease – the glaring contradictions related to how these policies repro-
duce forms of ‘stratiﬁed disability’ are completely ignored (cf. Ginsburg and Rapp 2013,
161). Some of these engagements reﬂect a broader ethical dilemma, earlier intimated in
Canguilhem’s idea of ‘undoing a false rhyme’ – i.e. the expanding use of genomics and
genetic tests seem to ‘erase the very category that you are trying to preserve’ (Friedner and
Weingarten 2016 for a review).
Concluding reﬂections
Earlier it was suggested that a language of epidemic and carriers reifying the body
as a ‘frontier of risk’ (Lock 2012) might silence the racialisation of historically and
socio-economically marginalised ethnic groups caught at the margins of the benevolent
and repressive functions of the state. India, in particular, has a long history of state abuse
of abortion and sterilisations as a means of controlling the re-productivity of such com-
munities (Jeffery and Jeffery 2011; Hodges 2006; Chattoo 1991). Given their economic
vulnerability, it is not difﬁcult to imagine how the political (in)visibility of ‘tribal health’
in general and IBDs in particular might constitute a space where the public health targets
of prevention and population control overlap. This is brought to sharp relief in a paper by
R S Balgir, a well-cited senior scientist (at the time, Deputy Director (ICMR) Regional
Medical Research Centre for Tribals, Jabalpur). Looking at the incidence of sickle cell and
other haemoglobin variants in a sample of 81 Dhelki Kharia tribal families from Sundar-
garh district in Orrisa, Balgir observes:
The poor, illiterate tribal communities, which are at the verge of extinction, can not afford
even the minimum standard of living and the treatment of an affected child is beyond their
expectation in India. The practical deprivation of infrastructural health facilities, lack of ade-
quate resources for treatment and lack of any source of entertainment in their isolated habi-
tat in the dense forest cover are the added disadvantages of the tribal communities in India.
Reproductive pleasure and sex life is the only entertainment source under such environmental
conditions.
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(further on)
… the tribal people go on producing children (2-6 children) regardless of their resources. If
the couple inherits any defective gene(s), those abnormal genes go on multiplying in the
community because of a large number of offspring productions. (2010, 360, my emphasis)
Balgir concludes that ‘There is an urgent need to contain the spread of preventable IBDs
in the underprivileged tribal communities in India’, by limiting the family size and pre-
venting new births with screening, counselling and prenatal diagnosis (361). Despite the
high infant mortality rate in the state, and the structural deprivation outlined by the
author, the national policy norm of the two child family is advocated as the hallmark of
development and women’s welfare. Furthermore, given the ﬁnancial constraints of mod-
ern life, all eligible (middle class and better educated) couples desire that, ‘every child
born should be normal’ (my emphasis, ibid, 362).
Indeed, the pressures of reproductive outcomes and prevention further complicate the
Indian case study when we think of how state sponsored genetic technologies might legiti-
mise the phenomenon of sex selective terminations of female foetuses affected by IBDs
(personal conversation with Yogesh Jain, 28 May 2017; see Gupta 2010; Ghai and Johri
2008; for a wider discussion see Unnithan-Kumar 2009; Patel 2007). Equally, the implica-
tions of an intersection of gender, genetics and disability set against vicissitudes of
extreme poverty shaping ‘local biologies’ of IBDs remain to be explored (cf. Locke and
Kaufert 2001).
In critically engaging with state policies of prevention, I do not wish to oppose and
romanticise family and community as benign and benevolent (Chattoo 2014; Das and
Addlakha 2007). Anthropological evidence points to the contingent and varied human
practices supporting abortion and neglect of fragile or physically impaired infants and
children, especially in communities facing extreme poverty and hunger (e.g. Denham,
2017; Allotey and Reidpath 2001; Scheper-Hughes 1996). Nevertheless, analytically,
we must treat negotiation of individual reproductive decisions including the use of pre-
natal technologies as distinct from state interventions for prevention of genetic disor-
ders. Not surprisingly, all the success stories of prevention represent authoritarian
regimes and some form of collusion between medicine, state and the Church/religion,
going right back to the thalassaemia eradication programme ﬁrst introduced in Cyprus
in 1974 (Kyriakedes 2016), and later imported to several Islamic states including
Pakistan.
Historical evidence suggests that prevention of births within the context of racialised/
ethnicised disorders often shifts resources away from care – reinforcing existing inequal-
ities in health as well as discriminatory attitudes towards difference and disability
(see Gammeltoft and Wahlberg 2014). Even though this seems less visible in the current
policy documents from India, we saw how the clinical literature, and anthropological
and census surveys (underpinning policy) reﬂect highly racialised notions of genes,
assuming caste/tribal groups as well as the diseases they embody to be stable, biological
entities. In following the WHO reclassiﬁcation of ‘preventable birth defects’ as an ethical
moment in global public health, two main conclusions can be drawn from the Indian
case study. First, as a result of the reclassiﬁcation, both the differences in history and the
complex molecular heterogeneity of thalassaemia/ sickle cell disorders is erased. This, in
turn, legitimises a policy focus on prevention – reinforcing forms of stratiﬁed
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reproduction as well as disability related to recessive gene disorders. Second, this erasure
works towards sequestrating meaningful debates on the social and ethical reverberations
of state policies on prevention. Hence, a critical engagement with the notion of child-
ren’s suffering highlights a systematic neglect within policy and practice of the long-
term treatment, education, employment and welfare support needs of millions of adults
living with these disorders.
I want to leave the reader with a passage in Afﬂiction, where Das reﬂects on a lack of
consensus in literature on how we might judge the ethical basis of state interventions,
especially when these relate to the poor, disabled or historically marginalised communities
(2015, 200). This, she notes, has replaced the earlier notion of public health where the
demarcation between the infectious and non-infectious diseases also delineated the
boundaries between the public and the private. She asks:
When would the kind of paternalism that deﬁnes such default conditions as provision of
clean drinking water slip into authoritarian control over individual rights? Given that public
health historically has been in close alliance with police and military operations and that
even now the most spectacular success stories of public health have emerged from strongly
authoritarian regimes (China, Rwanda), what place can we make to discuss cases in which
individuals prefer … liberty or dignity, over heath narrowly or even broadly deﬁned? (Das
2015, 200–2001)
Notes
1. This is not to underestimate the role of epigenetics, and the social, environmental and material
factors in explaining phenotypic difference, in the so-called post-genomic era (see Lock 2012
for a commentary).
2. I am ignoring the contrasting positions on prevention adopted by the Global Sickle Cell Dis-
ease Network (GSCDN) and Thalassaemia International Federation (TIF), and how these may
or may not impinge on the policies and practices of the NGOs at a local/ national level in India
(see Bivins 2015, 304–367).
3. Inherited blood disorders, globalisation and the promise of genomics: an Indian case-study
(2016–2019), with colleagues Karl Atkin (York), Veena Das (JHU) and Maya Unnithan
(Sussex) (Inherited blood disorders…: an Indian case-study).
4. The incidence of IBDs is higher in malaria endemic regions of the world; carriers are believed
to have developed a selective protection against Plasmodium falciparum that causes malaria
(Piel et al. 2014, 2).
5. Several local NGOs have been involved in screening, treatment and counselling for IBDs in the
tribal areas, long before the visibility of IBDs at an international level, e.g. Tribal India Health
Foundation, Gudalur, in the South and the Maharashtra Arogya Mandal in Pune.
6. Shobha Tuli is also the Vice President of TIF – who support national control programmes for
the prevention and treatment of thalassaemia across countries (www.thalassaemia.org.cy/
about-tif/). In contrast, the GSCDN focuses on research and clinical care to improve the lives
of children living with sickle cell and their communities (www.globalsicklecelldisease.org/).
However, TIF has now widened their base to cover sickle cell and other rare genetic disorders
and has a signiﬁcant online representation of patient and community groups across the world.
7. In August 2016, Namitha started an online petition submitted to the Union Health Minister
(.@JP nada:save our lives.), raising the issue of shortage of Desferal, a blood chelation drug,
produced by Novartis (a Swiss multinational) and the need to list it as an essential drug in the
state.
8. I have also read several posts about families struggling with treatment costs and premature
deaths of young people in their 20s due to lack of affordable chelation therapies across Pakistan
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and rural India. Perhaps, in scenarios of high levels of poverty and lack of access to basic treat-
ment, prevention operates in a different moral economy of care?
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